系统生物学和定量系统药理学的机会,以解决怀孕中药物开发的知识差距
Jeffrey S Barrett1, Karim Azer2
1Aridhia Digital Research Environment, Glasgow, UK.
Journal of clinical pharmacology
|June 15, 2023
概括
孕妇是药物研究中的治疗孤儿. 量化系统药理 (QSP) 模型与现实数据和人工智能相结合,可以改善对该群体的药物安全性评估和临床试验设计.
科学领域:
- 药理学 药理学是指药理学的学科.
- 翻译研究是翻译研究.
- 计算生物学 计算生物学
背景情况:
- 孕妇经常被排除在临床试验之外,导致怀孕期间缺乏关于药物安全性和有效性的数据.
- 目前针对孕妇群体的药物研究受到昂贵的毒理学研究和不足的临床试验的限制.
- 这种排斥造成了知识差距,使孕妇成为许多必要的药物治疗的"治疗孤儿".
研究的目的:
- 为应对孕妇药物研究中的挑战.
- 提出定量系统药理 (QSP) 建模作为风险评估和临床试验设计的解决方案.
- 探索现实数据和人工智能/机器学习 (AI/ML) 的整合,以推进该领域的研究.
主要方法:
- 对孕妇药物研究当前挑战的审查.
- 关于量化系统药理 (QSP) 模型开发的建议.
- 整合现实世界数据 (RWD) 和人工智能/机器学习 (AI/ML) 方法.
主要成果:
- 质量标准模型可以填补知识差距,使孕妇在怀孕期间使用药物的风险评估能够更早,更明智地进行.
- QSP模型可以优化临床试验设计,包括生物标志物选择,终点确定和样本大小.
- 将QSP与RWD和AI/ML相结合,为了解怀孕期间药物影响取得重大进展提供了机会.
结论:
- 定量系统药理 (QSP) 建模是减轻孕妇药理疗相关风险的有希望的方法.
- 整合现实世界的数据和AI/ML可以进一步增强QSP模型,以改善药物开发和安全性.
- 开放式科学模型和多学科合作对于推进怀孕中药物研究至关重要.
更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.1K
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
9.8K
相关概念视频
Biopharmaceutics and Pharmacokinetics: Overview
2.2K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.2K
Pharmacokinetic Models: Overview
818
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
818
Structure-Activity Relationships and Drug Design
800
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
800
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Model Approaches for Pharmacokinetic Data: Physiological Models
79
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
79
